Why Investors Are Interested in Anthem Biosciences IPO GMP
- Fast-Growing Sector – Biotech and CRDMO services are expanding rapidly.
- Strong Client Base – Partnerships with global pharma giants.
- Solid Margins – Healthy profitability over the years.
- Zero Fresh Issue – Existing shareholders selling shares; no dilution of equity.
- Anchor Investors Backing – Top funds participated pre-IPO.
Expert View: What Should You Do Now?
For Short-Term Traders:
If you invested during IPO, booking partial profits may be wise. The stock saw a 27% spike—locking gains is safe before volatility kicks in.
For Long-Term Investors:
If you believe in India’s biotech future, Anthem offers long-term growth potential. Strong financials and industry demand support a “buy and hold” approach.
Post-IPO Outlook: What to Expect
Here’s what analysts and investors are watching post-listing:
- Q1 & Q2 Results – Will determine if the valuation holds.
- Client Expansion – Global deals can push growth.
- R&D Pipeline – Innovation in CRDMO space will attract investor trust.
- Stock Price Movement – Will it stay above ₹700+ or consolidate?
Anthem’s performance in the coming quarters will decide whether it becomes a long-term wealth generator.
Pros and Cons Summary
| Pros | Cons |
|---|---|
| Strong listing gain (27%) | Slightly lower than GMP |
| High GMP indicates investor demand | Expensive valuation (~50× PE) |
| Strong financials & margins | No fresh capital raised |
| CRDMO sector tailwinds | Competition from Syngene, Divi’s Labs |
Real-Life Investor Example
A retail investor who got allotment at ₹570 saw the stock list at ₹723. That’s a gain of ₹153 per share. For 1 lot (26 shares), the profit was ₹3,978 on Day 1 itself.
FAQs
Q1. What was Anthem Biosciences’ GMP before listing?
GMP hovered between ₹165 and ₹177, indicating a strong positive sentiment.
Q2. How much return did IPO investors get on listing day?
Investors saw a ~27% return on the listing day, with the stock opening at ₹723.
Q3. Is it safe to buy Anthem Biosciences stock now?
If you’re a long-term investor, it can be a good pick based on strong fundamentals. Short-term traders should watch for price correction.
Q4. Was the IPO fully fresh issue or OFS?
It was a complete Offer For Sale (OFS); no new shares were issued.
Q5. Will the price rise further in the coming months?
That depends on financial performance and global biotech demand. Keep track of earnings and expansion news.
Know more related :
India Stock Market Opening & Closing Timings Explained
Anthem Biosciences IPO GMP & Share Price 2025
60865
